How Cancer Cells Manipulate Cellular Proteins

🔥When Cancer Outsmarts Treatment, Science Must Outthink Cancer🔥 A recent Science Advances paper caught my attention, not just as a physician, but as someone who has spent decades watching cancer evolve faster than our therapies. The study reveals a critical mechanism in EGFR-mutant non-small cell lung cancer (NSCLC): 🧬 cancer cells don’t just mutate to resist drugs , they actively protect those mutations. 🔬 The key insight: Mutant EGFR proteins are stabilised by a newly identified P2Y2–integrin axis, driven by high extracellular ATP. This “protective shield” prevents EGFR degradation, allowing cancer cells to survive and thrive despite EGFR-TKI therapy. In simple terms: 👉 The cancer cell builds a biochemical bunker around its most dangerous mutation. ⚛️ What’s compelling is that when researchers disrupted this axis via P2Y2, FAK, or ATP-related pathways, especially in combination with TKIs , drug resistance weakened and tumour growth slowed. 👨⚕️ My perspective as a doctor: For years, we’ve focused almost exclusively on blocking the signal. This research reminds us that stability, trafficking, and cellular context matter just as much. 💎 Cancer is not static. It adapts, shields itself, and rewires survival pathways. ⚛️ Future oncology will not be: • One drug • One target • One pathway 👉 It will be systems-based, combination-driven, and biology-respecting. This is how we move from: ❌ chasing resistance ➡️ anticipating it And ultimately, this is how precision medicine becomes truly precise. 👉 Science like this gives hope not hype for patients facing resistant disease. Aspire. Inspire. Achieve.

Cancer thrives by rewriting genetic instructions, often skipping “poison exons”—tiny bits of RNA that normally act as built-in kill switches to keep runaway growth in check. In many aggressive cancers, one such gene regulator, TRA2β , escapes this safeguard, fueling rapid tumor spread and worsening survival. Now, scientists at The Jackson Laboratory and UConn Health have found a way to flip that switch back on. Using antisense oligonucleotides (ASOs) —precisely engineered RNA strands—they forced poison exons back into TRA2β’s RNA messages. This trick caused cancer cells to destroy their own growth signals. The therapy, tested in cell cultures, 3D tumor organoids, and mouse models with patient-derived tumors, dramatically slowed or shrank cancer growth. The surprise? Poison-exon RNAs didn’t just silence TRA2β—they also trapped other proteins vital for cancer survival, creating a double blow that disrupted key pathways like p53 and mTOR . Analysis of thousands of tumor samples from The Cancer Genome Atlas confirmed that patients with low poison exon activity had worse outcomes across cancers such as breast, lung, cervical, and leukemia. Research Paper 📄 DOI: 10.1038/s41467-025-56913-8

Src is inverted onto the cell surface in cancer cells. Interesting observation with potentially significant implications: Intracellular N-myristoylated proteins, such as Src, may be topologically inverted onto the cell surface in cancer and targeted. Editor’s summary Discovering cell surface proteins that are specific to cancer cells and not normal cells can create opportunities for safer delivery of toxic drugs to tumors. Delaveris et al. identified a family of proteins that are delivered to the cell surface in cancer but not in healthy tissues (see the Perspective by Pfannenstein and Meyer). One such protein is the cancer-promoting enzyme Src. The researchers developed antibodies that target the surface form of Src and showed that these anti-Src antibodies could specifically deliver toxic radioactive isotopes or recruit killer T cells to tumors in vivo. This work highlights the potential to increase the types of cell surface targets available for cancer therapies.

A new study published in Nature shows that the physical forces around a tumor can drive cancer cells to dramatically change their behavior. Instead of simply dividing quickly, cells under mechanical pressure can activate a program that makes them more invasive and resistant to treatment, adding new complexity to how cancers spread and survive. Researchers used a zebrafish model of melanoma to observe how tumor cells react when tightly confined by surrounding tissues. They discovered that the stress of confinement triggered a switch from rapid growth to what the team called “neuronal invasion,” enabling cells to migrate and infiltrate nearby tissue. At the heart of this transformation is HMGB2, a DNA-bending protein that changes how genetic material is packaged, exposing genes linked to invasiveness. The study also revealed that cancer cells protect themselves under stress by reshaping their internal skeleton, forming a cage-like structure around the nucleus. This involves the LINC complex, which connects the cell skeleton to the nuclear envelope and guards against DNA damage caused by pressure. The findings highlight how the tumor microenvironment plays an active role in shaping cancer progression. By identifying the proteins and structures involved in this switch, researchers hope to develop therapies that block or even reverse the transition to an invasive, drug-resistant state. Research Paper 📄 PMID: 40866703

Hot Topic of the Week:  Surface Antigen Camouflage and Antigen Expression Loss Tumors often use complex mechanisms to evade immune detection, two of which are surface antigen camouflage and loss of antigen expression. These evasion strategies weaken the immune system's ability to recognize and eliminate cancer cells, and therefore pose a major challenge to immunotherapy. (1) Surface antigen camouflage mechanism Cancer cells can mask their antigens by changing or hiding the molecular structure on their surface. Glycosylation is a key mechanism, in which cancer cells modify their surface proteins by adding sugar molecules to mask the recognition of immune cells. In addition, cancer cells can also use overexpression of surface molecules such as CD47 (known as the "don't eat me" signal) to inhibit macrophage-mediated phagocytosis. This camouflage protects tumors from immune surveillance and creates an immune-tolerant microenvironment. (2) Loss of antigen expression Tumors can evade immune detection by downregulating or completely losing the expression of key tumor-associated antigens (TAAs) or tumor-specific antigens (TSAs). This mechanism is particularly common in T cell-mediated immune responses, as T cells rely primarily on antigen presentation to recognize and attack cancer cells. The loss of antigen expression may occur through mutation, epigenetic modification, or selection pressure of immune response, resulting in the inability of antigen-presenting cells to effectively detect tumor cells. This phenomenon is also the main reason for the resistance of immunotherapies such as CAR-T cells targeting specific antigens. Taken together, these immune evasion strategies together highlight the dynamic interaction between cancer cells and the immune system. Understanding these mechanisms can provide important help in the development of next-generation immunotherapies. For example, scientists can choose to target glycosylation pathways, enhance antigen presentation, or design new CAR-T cells to recognize a wider range of antigens, bringing hope to overcome immune resistance. References [1] Anoop Kallingal et al., J Cancer Res Clin Oncol 2023 (doi: 10.1007/s00432-023-04737-8) [2] Kailin Yang et al., Nature Reviews Clinical Oncology 2023 (https://lnkd.in/e7j2Apah) #ImmuneEvasion #CancerImmunotherapy #AntigenCamouflage #TumorResistance #CAR_Therapy #ImmunoOncology #CancerResearch #InnovationInMedicine #TumorMicroenvironment

A new study led by researchers at Stony Brook Medicine, in collaboration with Yale School of Medicine and national partners, is shedding light on why one of the most aggressive forms of pancreatic cancer is so difficult to treat. Their research, published in Cancer Research, shows that a protein called K17 can influence how cancer cells use energy and build DNA components, ultimately making them less responsive to a commonly used treatment, gemcitabine. What makes this especially important is that it helps explain something clinicians have seen for years in the most aggressive form of pancreatic cancer, that higher K17 levels are linked to poorer outcomes. By better understanding how this protein works inside cancer cells, researchers are now pointing to a possible new vulnerability that could be targeted in future therapies. This is a strong example of collaborative science across institutions and of the ongoing work to better understand and ultimately change outcomes for patients facing this disease. https://bit.ly/4obiHAy